Two retrospective studies american conclude to the effectiveness of Hydroxychloroquine for reduced mortality of patients Covid-19 hospitalized
Following the previous articles on the performance of the various treatments for the Covid-19, two retrospective studies from the united states are published recently. We will let’s decrypt the lines in the article below. These two studies are in the process of igniting the canvas american, since they are repeated by CNN and the social networks. Many medical experts have criticized the studies on the hydroxychloroquine on the boards of the largest media and, for the first time, CNN seems to focus on these recent studies demonstrating a positive effect of the hydroxychloroquine. Could this be an early turning point in the american media? On this side of the atlantic, the European Agency of Medicinal product comes to recommend the remdesevir as a treatment for the Covid-19, despite important biases and side-effects. In France, except of course SudRadio and in our columns, it is the radio silence on these studies.
Retrospective study multivariate Hospitals of New York (1)
This study focuses on 6493 patients (median age 59 years) confirmed for the Covid-19. It describes the clinical characteristics of COVID-19 as an outpatient in a hospital environment and the identification of risk factors associated with mortality in hospitalized patients.
Factors associated with a lower risk of in-hospital mortality included female sex, race, african-american, and the use of hydroxychloroquine. The statistical adjustment did not result in significant change.
Retrospective study – Hospital Henry Ford of Detroit
This study focuses on 2 541 patients (median age 64 years) of the same hospital all tested positive for the virus, SARS-Cov-2. It is a cohort study retrospective comparative evaluating the clinical outcomes of all consecutive patients hospitalized at the Henry Ford Health System.
No torsades de pointes was not observed with the treatment with hydroxychloroquine.
Hydroxychloroquine alone has helped to reduce the ratio of risk of 66%, and hydroxychloroquine + azithromycin of 71% compared to none of the two treatments (p <0.001).
The curves of Kaplan-Meier survival showed a significant improvement in survival in patients hydroxychloroquine alone and hydroxychloroquine + azithromycin compared to groups not receiving hydroxychloroquine and those treated with azithromycin alone ( Fig.1 ).
The result of the Cox regression for the two groups matched on the propensity (table 4) indicates that treatment with hydroxychloroquine resulted in a decline in the ratio of mortality risk of 51% (p = 0.009)
Note : there is a 4.9-year age difference between the 2 groups at baseline. This bias is not erased with the multivariate analysis because there is a 50/50 split of the + 65 years of age. It is, however, strongly decreased.
In addition, the study in New york, above, has shown that the age starts to be a factor of mortality above the age of 65 (table 3). And the authors of this study gives also the estimate of 2.6 factor of mortality above the age of 65.
Author(s): The Citizens ‘ group for FranceSoir